Cataplexy, Excessive Sleepiness, Hypersomnolence, Narcolepsy, Sleep Disorders
Conditions
Brief summary
The primary objective is to evaluate the therapeutic effect of excessive daytime sleepiness associated with narcolepsy. Both of the subjective and objective sleepiness of the patients were assessed in the experiment by repeat measures.
Interventions
DRUGModafinil
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Polysomnographic findings of shortened sleep latency less than 5 minutes average of Multiple Sleep Latency Test, and two or more SOREM should be fulfilled. * Age of 12 y/o to 55 y/o. * The liver and kidney functions are within normal limits. * Meeting the strict criteria of narcolepsy described above. * Wash out any medications which might enhance wakefulness or affect nocturnal sleep two weeks prior to the experiments. * Willingness to comply with the protocol and signed the written Informed Consent.
Exclusion criteria
* Patients whose hypersomnia was caused by severely sleep deprived, phase delayed, or suspected long sleeper. * Patients with concomitant neurological disorder and psychiatric disorders. * Patients with sleep-related breathing disorders whose apnea/hypopnea index (AHI) was 5 pauses per hour above. * Patients with Restless Leg Syndrome & Periodic Limbs Movements whose index was more than 5 per hour. * Patients who are pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change from baseline in the sleep latency. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's assessment of general level of daytime sleepiness on ESS. | — |
| Patient's cognitive function assessed by psychomotor function test (Trail making test, and Digit Symbol Substitution Test). | — |
| Patient's sleep quality evaluated by PSQI. | — |
| Safety would be evaluated by tabulating and summarizing all adverse events reported. | — |
Outcome results
None listed